Amoy Diagnostics Co

Amoy Diagnostics Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Amoy Diagnostics Co (300685.SZ) as of Nov 5, 2026 is 27.54. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 22.70 — a change of 21.33% (higher).

EV/FCF

27.54

YoY

21.33%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Amoy Diagnostics Co is 2025 27.54 . EV/FCF (Enterprise Value to Free Cash Flow) of Amoy Diagnostics Co was 2024 22.70 . It decreases by 21.33% higher compared to the previous year.

The Amoy Diagnostics Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
143.76 CNY
Jan 1, 2019
58.45 CNY
Jan 1, 2020
45.60 CNY
Jan 1, 2021
78.04 CNY
Jan 1, 2022
103.43 CNY
Jan 1, 2023
27.76 CNY
Jan 1, 2024
22.70 CNY
Jan 1, 2025
27.54 CNY
The Amoy Diagnostics Co EV/FCF history
YEAREV/FCFYoY
27.54+21.33%
22.70-18.25%
27.76-73.16%
103.43+32.54%
78.04+71.15%
45.60-22.00%
58.45-59.34%
143.76+28.55%
111.83-118.88%
-592.49-20.37%
-744.03+182.68%
-263.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amoy Diagnostics Co Stock analysis

What does Amoy Diagnostics Co do? Amoy Diagnostics Co., Ltd. generates revenue through the sale of tumor precision molecular diagnostic products, including ADx-ARMS, Super-ARMS, NGS, and FISH testing reagents. These reagents are used for detecting non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma in tumor tissue specimens and liquid biopsies. The company also offers data software for gene sequencing data analysis and provides testing services via its medical testing institutions for lung cancer, colorectal cancer, and breast cancer. Revenue streams include reagent sales, software licensing, and diagnostic testing services. The primary customers are medical institutions and healthcare providers requiring tumor molecular diagnostics. The ADx-ARMS product line targets tumor tissue specimen detection, while Super-ARMS serves liquid biopsy applications. NGS and FISH products support comprehensive tumor genetic analysis. Testing services focus on lung, colorectal, and breast cancer diagnostics, catering to hospitals and clinics specializing in oncology. The company’s offerings align with the demand for precise cancer diagnosis and treatment planning. Amoy Diagnostics’ revenue model combines product sales with service-based offerings. Reagent products like ADx-ARMS and Super-ARMS are sold to medical facilities for routine tumor testing. Data software for gene sequencing analysis is licensed to research institutions and hospitals. Testing services through its medical testing institutions provide direct diagnostic solutions for specific cancers, enhancing customer retention through integrated service packages. Amoy Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amoy Diagnostics Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Amoy Diagnostics Co is 27.54 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Amoy Diagnostics Co changed from 22.70 to 27.54, representing a 21.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Amoy Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Amoy Diagnostics Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Amoy Diagnostics Co

All Key Metrics — Amoy Diagnostics Co